Literature DB >> 22044206

DNA damage response and repair: insights into strategies for radiation sensitization of gliomas.

Santosh Kesari1, Sunil J Advani, Joshua D Lawson, Kristopher T Kahle, Kimberly Ng, Bob Carter, Clark C Chen.   

Abstract

The incorporation of radiotherapy into multimodality treatment plans has led to significant improvements in glioma patient survival. However, local recurrence from glioma resistance to ionizing radiation remains a therapeutic challenge. The tumoricidal effect of radiation therapy is largely attributed to the induction of dsDNA breaks (DSBs). In the past decade, there have been tremendous strides in understanding the molecular mechanisms underlying DSB repair. The identification of gene products required for DSB repair has provided novel therapeutic targets. Recent studies revealed that many US FDA-approved cancer agents inhibit DSB repair by interacting with repair proteins. This article will aim to provide discussion of DSB repair mechanisms to provide molecular targets for radiation sensitization of gliomas and a discussion of FDA-approved cancer therapies that modulate DSB repair to highlight opportunities for combination therapy with radiotherapy for glioma therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22044206      PMCID: PMC3236247          DOI: 10.2217/fon.11.111

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  101 in total

1.  RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins.

Authors:  Carsten Doil; Niels Mailand; Simon Bekker-Jensen; Patrice Menard; Dorthe Helena Larsen; Rainer Pepperkok; Jan Ellenberg; Stephanie Panier; Daniel Durocher; Jiri Bartek; Jiri Lukas; Claudia Lukas
Journal:  Cell       Date:  2009-02-06       Impact factor: 41.582

Review 2.  Targeting the DNA damage response in cancer.

Authors:  Mats Ljungman
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

3.  Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Authors:  Michael D Prados; Susan M Chang; Nicholas Butowski; Rebecca DeBoer; Rupa Parvataneni; Hannah Carliner; Paul Kabuubi; Jennifer Ayers-Ringler; Jane Rabbitt; Margaretta Page; Anne Fedoroff; Penny K Sneed; Mitchel S Berger; Michael W McDermott; Andrew T Parsa; Scott Vandenberg; C David James; Kathleen R Lamborn; David Stokoe; Daphne A Haas-Kogan
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

Review 4.  Mechanisms of double-strand break repair in somatic mammalian cells.

Authors:  Andrea J Hartlerode; Ralph Scully
Journal:  Biochem J       Date:  2009-09-25       Impact factor: 3.857

5.  Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.

Authors:  Gregory J Kubicek; Maria Werner-Wasik; Mitchell Machtay; Gayle Mallon; Thomas Myers; Michael Ramirez; David Andrews; Walter J Curran; Adam P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-10       Impact factor: 7.038

6.  Principles of cancer therapy: oncogene and non-oncogene addiction.

Authors:  Ji Luo; Nicole L Solimini; Stephen J Elledge
Journal:  Cell       Date:  2009-03-06       Impact factor: 41.582

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.

Authors:  Bipasha Mukherjee; Brian McEllin; Cristel V Camacho; Nozomi Tomimatsu; Shyam Sirasanagandala; Suraj Nannepaga; Kimmo J Hatanpaa; Bruce Mickey; Christopher Madden; Elizabeth Maher; David A Boothman; Frank Furnari; Webster K Cavenee; Robert M Bachoo; Sandeep Burma
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

9.  Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage.

Authors:  Neil Johnson; Dongpo Cai; Richard D Kennedy; Shailja Pathania; Mansi Arora; Yu-Chen Li; Alan D D'Andrea; Jeffrey D Parvin; Geoffrey I Shapiro
Journal:  Mol Cell       Date:  2009-08-14       Impact factor: 17.970

10.  Multiple functions of MRN in end-joining pathways during isotype class switching.

Authors:  Maria Dinkelmann; Elizabeth Spehalski; Trina Stoneham; Jeffrey Buis; Yipin Wu; JoAnn M Sekiguchi; David O Ferguson
Journal:  Nat Struct Mol Biol       Date:  2009-07-26       Impact factor: 15.369

View more
  20 in total

1.  PARP3 interacts with FoxM1 to confer glioblastoma cell radioresistance.

Authors:  Jun-Jie Quan; Jin-Ning Song; Jian-Qiang Qu
Journal:  Tumour Biol       Date:  2015-06-04

Review 2.  Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.

Authors:  David R Raleigh; Daphne A Haas-Kogan
Journal:  Future Oncol       Date:  2013-02       Impact factor: 3.404

3.  Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.

Authors:  Dina V Hingorani; Matthew K Doan; Maria F Camargo; Joseph Aguilera; Seung M Song; Donald Pizzo; Daniel J Scanderbeg; Ezra E W Cohen; Andrew M Lowy; Stephen R Adams; Sunil J Advani
Journal:  Mol Cancer Ther       Date:  2019-10-09       Impact factor: 6.261

4.  LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway.

Authors:  Ji-An Yang; Bao-Hui Liu; Ling-Min Shao; Zhen-Tao Guo; Qian Yang; Li-Quan Wu; Bao-Wei Ji; Xiao-Nan Zhu; Shen-Qi Zhang; Cheng-Jun Li; Qian-Xue Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

5.  TCN, an AKT inhibitor, exhibits potent antitumor activity and enhances radiosensitivity in hypoxic esophageal squamous cell carcinoma in vitro and in vivo.

Authors:  Qing Guo; Jia He; Feng Shen; Wei Zhang; Xi Yang; Chi Zhang; Qu Zhang; Jun-Xing Huang; Zheng-Dong Wu; Xin-Chen Sun; Sheng-Bin Dai
Journal:  Oncol Lett       Date:  2016-12-20       Impact factor: 2.967

6.  Long-term follow-up of lateral ventricular central neurocytoma treated with subtotal resection followed by concurrent chemoradiotherapy and add on chemotherapy - Case report from a Tertiary Kenyan Cancer Hospital.

Authors:  Vijayakumar Narayanan; Kiboi Julius; James Mbogo
Journal:  Surg Neurol Int       Date:  2020-09-05

7.  Radiosensitizing effect of dendrosomal nanoformulation of curcumin on cancer cells.

Authors:  Tahereh Jalali Varnamkhasti; Meisam Jafarzadeh; Majid Sadeghizadeh; Mahdi Aghili
Journal:  Pharmacol Rep       Date:  2022-07-10       Impact factor: 3.919

8.  Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma.

Authors:  J Dawn Waters; Brent Rose; David D Gonda; Daniel J Scanderbeg; Michelle Russell; John F Alksne; Kevin Murphy; Bob S Carter; Joshua Lawson; Clark C Chen
Journal:  J Neurooncol       Date:  2013-05-15       Impact factor: 4.130

9.  Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.

Authors:  M Balducci; A Fiorentino; P De Bonis; S Chiesa; A Mangiola; G C Mattiucci; G R D'Agostino; V Frascino; G Mantini; A R Alitto; C Colosimo; C Anile; V Valentini
Journal:  Strahlenther Onkol       Date:  2013-08-24       Impact factor: 3.621

10.  Genetic polymorphisms of DNA double-strand break repair pathway genes and glioma susceptibility.

Authors:  Peng Zhao; Peng Zou; Lin Zhao; Wei Yan; Chunsheng Kang; Tao Jiang; Yongping You
Journal:  BMC Cancer       Date:  2013-05-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.